Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma

Researchers used the combination of interim PET results and the presence or absence of an associated IgM gammopathy among patients with DLBCL to dichotomize the population into sizeable high-risk (ie, 1-2 adverse factors) and low-risk groups (ie, no adverse factors) and found widely different outcomes: population size, 25% vs. 75%; 3-year risk of progression, 51% vs. 10%; and 3-year overall survival, 64% vs. 95%.